Nurix Therapeutics Quarterly Income Statement
NASDAQ: NRIXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Nurix Therapeutics revenue and earnings
In the quarter ended May 31, 2026, Nurix Therapeutics generated $9.0 million in revenue, down 79.5% from the same quarter a year earlier. Nurix Therapeutics reported a net loss of $89.5 million, compared with a loss of $43.5 million a year earlier. Operating margin was -1041.7%.
Diluted earnings per share came in at -$0.81.
Summary generated from market data by MetaCap's automated system. Methodology
Nurix Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-05-31 | Q1 20262026-02-28 | Q4 20252025-11-30 | Q3 20252025-08-31 | Q2 20252025-05-31 | Q1 20252025-02-28 | Q4 20242024-11-30 | Q3 20242024-08-31 | Q2 20242024-05-31 | Q1 20242024-02-29 | Q4 20232023-11-30 | Q3 20232023-08-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.04M | 6.25M | 13.58M | 7.89M | 44.06M | 18.45M | 13.28M | 12.59M | 12.09M | 16.59M | 15.16M | 18.47M |
| Revenue growth (YoY) | -79.47% | -66.12% | +2.21% | -37.29% | +264.34% | +11.26% | -12.37% | -31.84% | -60.58% | +30.74% | +123.49% | +71.13% |
| Operating Expenses | 103.25M | 98.75M | 96.67M | 99.28M | 92.38M | 81.32M | 77.94M | 67.20M | 60.63M | 61.80M | 60.49M | 58.48M |
| Research & Development | 87.65M | 84.14M | 83.02M | 86.12M | 78.10M | 69.66M | 67.22M | 55.48M | 48.92M | 50.01M | 49.71M | 47.86M |
| Operating Income | -94.20M | -92.50M | -83.09M | -91.39M | -48.32M | -62.86M | -64.66M | -54.61M | -48.54M | -45.22M | -45.33M | -40.01M |
| Pretax Income | -89.81M | — | -78.22M | -86.42M | -42.70M | -56.35M | -58.54M | -48.87M | -44.46M | -41.43M | -41.96M | -36.98M |
| Income Tax | -271.00K | 0 | 0 | 0 | 760.00K | 0 | 8.00K | 82.00K | 90.00K | 90.00K | 0 | 0 |
| Net Income | -89.53M | -87.17M | -78.22M | -86.42M | -43.46M | -56.35M | -58.55M | -48.96M | -44.55M | -41.52M | -41.96M | -36.98M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.81 | -0.79 | -0.83 | -1.03 | -0.52 | -0.67 | -0.74 | -0.67 | -0.71 | -0.76 | -0.77 | -0.68 |
| EPS (Diluted) | -0.81 | -0.79 | -0.83 | -1.03 | -0.52 | -0.67 | -0.74 | -0.67 | -0.71 | -0.76 | -0.77 | -0.68 |
| Shares Outstanding (Basic) | 111.08M | 110.07M | — | 84.16M | 83.88M | 83.56M | — | 72.78M | 62.38M | 54.90M | — | 54.39M |
| Shares Outstanding (Diluted) | 111.08M | 110.07M | — | 84.16M | 83.88M | 83.56M | — | 72.78M | 62.38M | 54.90M | — | 54.39M |
| EBITDA | -91.95M | -90.30M | -80.97M | -89.36M | -46.08M | -60.51M | -62.11M | -52.22M | -46.21M | -43.17M | -43.40M | -38.06M |
| Operating Margin | -1041.73% | -1479.45% | -612.03% | -1157.65% | -109.68% | -340.67% | -486.73% | -433.83% | -401.42% | -272.65% | -299.06% | -216.67% |
| Net Margin | -990.10% | -1394.34% | -576.13% | -1094.77% | -98.66% | -305.38% | -440.75% | -388.91% | -368.39% | -250.33% | -276.77% | -200.26% |
This table shows 12 quarterly periods of Nurix Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 14 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow NRIX's reporting calendar. What is a income statement?